



HAL
open science

Effects of 17β -Estradiol on Preadipocyte Proliferation in Human Adipose Tissue: Involvement of IGF1-R Signaling

Esther dos Santos, Marie-Noelle Dieudonné, Marie-Christine Leneveu, Valérie Sérazin, Vincent Rincheval, Bernard Mignotte, Etienne Chouillard, Philippe de Mazancourt, Yves Giudicelli, René Pecquery

► **To cite this version:**

Esther dos Santos, Marie-Noelle Dieudonné, Marie-Christine Leneveu, Valérie Sérazin, Vincent Rincheval, et al.. Effects of 17β -Estradiol on Preadipocyte Proliferation in Human Adipose Tissue: Involvement of IGF1-R Signaling. *Hormone and Metabolic Research*, 2010, 42 (07), pp.514-520. <10.1055/s-0030-1249639>. <hal-04003909>

HAL Id: hal-04003909

<https://uvsq.hal.science/hal-04003909v1>

Submitted on 24 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>alpha isoform. We also showed that 17β-estradiol is able to inhibit human preadipocyte apoptosis capacity as reflected by DNA fragmentation experiments and the mRNA expression of the pro- and anti-apoptotic genes. Finally, 17β-estradiol via ER-alpha significantly induces both mRNA and protein expression of IGF1 receptor in human preadipose cells and thus reinforces the signalling pathway of the proliferative factor, IGF1. Taken together, these data reinforce the concept of cross-talk between IGF1- and estrogen receptor-signalling pathways in preadipocytes and indicate that IGF1 may be a critical regulator of estrogen-mediated preadipose growth.</p>



For Peer Review

1
2 **EFFECTS OF 17 β -ESTRADIOL ON PREADIPOCYTE PROLIFERATION IN HUMAN**
3
4 **ADIPOSE TISSUE : INVOLVEMENT OF IGF1-R SIGNALLING**
5
6
7

8
9 Dos Santos E^{1*}, Dieudonné MN¹, Leneveu MC¹, Sérazin V¹, Rincheval V², Mignotte B², Chouillard E³
10
11 De Mazancourt P¹, Giudicelli Y¹ and Pecquery R¹
12
13

14
15
16
17 *¹ Service de Biochimie et Biologie Moléculaire, UPRES EA 2493, Faculté de Médecine Paris-Ile de*
18
19 *France Ouest, Université Versailles St Quentin, PRES Universud Paris, Centre hospitalier de Poissy,*
20
21 *78303 Poissy Cedex FRANCE.*
22

23
24
25
26 *² Laboratoire de Génétique et Biologie cellulaire, UMR 8159 CNRS, Université Versailles St Quentin,*
27
28 *PRES Universud Paris.*
29

30
31
32
33 *³ Service de Chirurgie Viscérale, Centre hospitalier de Poissy, 78303 Poissy Cedex FRANCE.*
34
35

36
37
38 * to whom correspondence should be addressed
39

40 address: Service de Biologie Médicale, Centre Hospitalier, 78303 Poissy Cedex FRANCE.
41
42

43
44
45 Phone number : 33 1 39 27 51 40
46

47 Fax number : 33 1 39 27 44 20
48

49 Email : biochip@ wanadoo.fr.
50
51

52
53
54
55 **Keywords:** human adipose tissue, estrogens, proliferation, IGF1 receptor, apoptosis
56
57

Abstract

Estrogens are known to stimulate the proliferation of human preadipocytes. However, the molecular mechanisms underlying the increased cell growth by these steroids are poorly understood. In the present study, we have demonstrated that the proliferative effect of 17β -estradiol involves the induction of both cell cycle gene expressions, c-myc and cyclin D1. Moreover, the mitogenic effects of 17β -estradiol are suppressed by the pure antagonist ICI 182,780 suggesting that estradiol action is mediated by estrogen receptor α isoform. We also showed that 17β -estradiol is able to inhibit human preadipocyte apoptosis capacity as reflected by DNA fragmentation experiments and the mRNA expression of the pro- and anti-apoptotic genes. Finally, 17β -estradiol *via* ER α significantly induces both mRNA and protein expression of IGF1 receptor in human preadipose cells and thus reinforces the signalling pathway of the proliferative factor, IGF1.

Taken together, these data reinforce the concept of cross-talk between IGF1- and estrogen receptor-signalling pathways in preadipocytes and indicate that IGFI may be a critical regulator of estrogen-mediated preadipose growth.

Introduction

It is well established that adipose tissue development and distribution are tightly regulated by sex steroid hormones [1, 2]. Different studies reveal that these hormones and more particularly estrogens affect fat mass by altering both adipocyte number and size [3]. Indeed, recent experiments demonstrated that estrogens modulate lipid storage and mobilization capacities in human adipocytes principally i) through decreasing expression and activity of lipoprotein lipase, an enzyme that regulates lipid uptake by adipocytes [4], ii) through inducing the lipolytic enzyme hormone-sensitive lipase [5] and iii) attenuating α_2 -adrenergic antilipolytic receptor expression [6]. Two other studies revealed that in human adipose tissue estrogens may increase the rate of proliferation *in vitro* [7, 8] without altering the differentiation process [1]. The two specific nuclear receptors (ER) α and β which mediate biological effects of estrogens are present in both human precursors and mature fat cells indicating a auto/paracrine action of these hormones [9]. It has been demonstrated that ER α is the main receptor in adipose cells [10, 11]. However, the molecular mechanisms by which estrogens modulate adipose biology are not clearly understood.

In various cell types, regulation of growth by estrogens seems to be mediated, at least in part, through changes in the expression of some growth factors and/or their receptors. Among these growth factors, Insulin-like Growth Factor 1 (IGF1) is considered as an important mitogenic factor in human adipose tissue [12]. Indeed, a growing body of evidence suggest that IGF1- and estrogen-mediated signalling pathway are cross-linked [13]. First, estrogens have been reported to alter expression of nearly all of the IGF family members including IGF1, IGF-binding proteins, IGF1 receptors (IGF1-R), and insulin receptor substrate 1 [14, 15]. Furthermore, ligand-bound ER has been described to activate IGF1 pathway by direct binding and activation of IGF1-R [16] or by directly binding to the p85 subunit

1
2 of PI3 kinase and the tyrosine kinase Src leading to activation of the PI3 kinase [17, 18]. Reciprocally,
3
4 recent studies have reported that IGF1 signalling pathway may enhance ER expression and function by
5
6 inducing phosphorylation of ER [19, 20]. Moreover, several studies have described synergistic effects
7
8 of the combination of estrogens and IGF1 on cell cycle regulation in breast tumor cell lines [13].
9

10
11 In the present study, we have explored the *in vitro* effects of estrogens on human adipose growth
12
13 in order to identify target genes that could be important for the estrogen action on adiposity with
14
15 particular focus on the role of IGF1-R signalling.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Materials

DMEM-Ham's F12 (50:50 mix), penicillin, streptomycin, leupeptin, aprotinin, AEBSEF, 17 β -estradiol and bovine serum albumin (BSA) were purchased from Sigma Chemical Co. (St Louis, Mo, USA). Collagenase was from Roche Molecular Biochemicals (Mannheim, Germany). Superscript II Rnase H-RT was provided by Gibco BRL (Grand Island, NY, USA), Taq polymerase and RNA guard were by Pharmacia Biotechnology (Uppsala, Sweden), the antiserum specific for active MAP kinase was by Promega Corp (Madison, WI, USA). ICI 182780 was from Tocris (Bristol, UK). Polyclonal rabbit anti-IGF1-R antiserum was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The antiserum specific for the non phosphorylated forms of MAPK was obtained from Transduction Laboratories (Lexington, WI, USA). Fetal calf serum (FCS) was obtained from Gibco-BRL (Grand Island, NY, USA). [³H]-thymidine was from Amersham (Buckinghamshire, UK).

Subjects

The adipose tissue donor group included 9 post-menopausal women (age 64 \pm 10 years; BMI: 21.9 \pm 1.1 kg/m²) and 16 men (age 63 \pm 12 years; BMI: 26.3 \pm 3.5 kg/m²) undergoing surgical intervention. None of these patients suffered from endocrine malignant or chronic inflammatory diseases. This study was approved by patient's written consent and by the local Ethical Committee (CCPPRB).

Cell culture and treatment

The adipose tissue samples (25-50 g) obtained from subcutaneous fat depots were collected in

1
2 saline (NaCl 150 mM) and immediately transferred to the laboratory. After removing blood vessels and
3
4 connective tissue, adipose tissue was rinsed in saline containing antibiotics (100 U/ml penicillin and 0.1
5
6 mg/ml streptomycin). Preadipocytes were obtained by collagenase digestion as previously described
7
8 [21]. Preadipocytes were plated in DMEM/F12 supplemented with streptomycin (0.1 mg/ml), penicillin
9
10 (100 U/ml) and 10% FCS and maintained at 37°C under 5% CO₂, 95% air atmosphere. After plating at
11
12 2-3 x 10⁴ cells cm⁻², cells which exhibited a fibroblast-like morphology were extensively washed and
13
14 maintained in DMEM/F12 supplemented with antibiotics and 10% FCS until confluence (3-4 days after
15
16 plating) and then treated with estrogens or vehicle. The effects of estrogens were essentially the same
17
18 whatever the sex of the donors was. Therefore, most of the data shown herein are means of the results
19
20 of pooled experiments performed in both men and women cells.
21
22
23
24
25
26
27
28

29 **[³H]-thymidine incorporation**

30
31 Human preadipose cells were suspended in 12-well plates containing DMEM-Ham's
32
33 supplemented with 10% FCS. During the exponential growing phase, the culture medium was replaced
34
35 by DMEM-Ham's containing 2% charcoal-stripped FCS during 24 h. For the next 24 h, cells were
36
37 exposed to 100 nM 17β-estradiol or to 10 μM ICI 182,780 with or without 100 nM 17β-estradiol in
38
39 the presence of [³H]-thymidine (1 mCi/ml). After washing 3 times with saline, cells were lysed during 5
40
41 min with 1% SDS and treated with 10% trichloroacetic acid for 45 min at 4°C. Radioactivity was
42
43 counted after filtration on GF/C filters (Whatman, Clifton, NY).
44
45
46
47
48
49

50 **Cell counting**

51
52 The experimental design used was that described above. Cells were trypsinized with calcium-
53
54 and magnesium-free Hank's solution containing 0.2% trypsin. Finally, cells were counted in a
55
56
57
58
59
60

1
2 hemocytometer after 24 h of treatment with 100 nM 17 β -estradiol or control.
3
4
5
6

7 **Apoptosis Assay**

8
9 After 18 h in DMEM/F12 supplemented with 2% charcoal-stripped FCS, cells were cultured
10 during 24 h in the presence of TNF α (50 ng/ml) and cycloheximide (10 μ g/ml) in order to induce
11 apoptosis of human preadipocytes as described in [22, 23]. Then after, once apoptosis was triggered,
12 cells were maintained in the same medium during 48 h and treated or not with 17 β -estradiol (100 nM)
13 or with the known antiapoptotic factor, IGF1 (10 nM), or control. Attached cells were harvested by
14 trypsinisation, combined with floating cells and suspended in PBS at a density of 10⁶ cells/ml. Then,
15 cells were fixed in 70% ethanol at -20°C overnight and washed twice with PBS. Cells were labeled for
16 DNA fragmentation by TUNEL according to the instructions provided by the manufacturer. Apototic
17 index was calculated after counting a minimum of 5000 events by flow cytometry using an EPICS flow
18 cytometer (Coulter Electronics, Miami, USA).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **IGF1-R immunoprecipitation**

40 At confluence, the culture medium of preadipocytes was replaced by DMEM-Ham's containing
41 2% charcoal-stripped FCS during 24 h. For the next 24 h, 17 β -estradiol (100 nM) was added to the
42 culture medium. Preadipocytes were then lysed in a immunoprecipitation buffer containing 1% triton
43 X-100, NaCl 150 mM, 10 mM Tris ph 7.4, EDTA 1 mM, EGTA 1 mM ph 8, 0.2 mM sodium ortho-
44 vanadate, 0.2 mM PMSF, 0.5% NP-40, 1 mM sodium vanadate, 20 μ g/ml AEBSF, 30 mM β -
45 glycerophosphate, 5 μ g/ml aprotinin, and 12.5 μ g/ml leupeptin. After maintained in a constant agitation
46 for 30 min at 4°C, microcentrifuge tubes were centrifugated at 100,000 x g for 10 min at 4°C. Equal
47 amounts (200-300 μ g) of the supernatant containing the "total cell lysate" were immunoprecipitated
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 with 5 μg of anti-IGF1-R antibody overnight at 4°C in the immunoprecipitation buffer.
3
4 Immunocomplexes were captured by adding 40 μl of Protein A/G plus : Agarose for 5 h at 4°C. The
5
6 pellet was collected by centrifugation at 8000g for 1 min at 4°C. After two washes in the
7
8 immunoprecipitation buffer, the pellet was resuspended in 30 μl of Laemmli's buffer, boiled for 5 min
9
10 and centrifuged for 5 min at 16.000 g. Immunoprecipitated proteins were then fractioned on SDS-
11
12 PAGE (7%). Controls used included the omission of cell lysates or the anti-IGF1-R antibody during
13
14 immunoprecipitation. Proteins were transferred to PVDF membrane and blocked in buffer A (20 mM
15
16 Tris HCl, 137 mM NaCl and 0.1% Tween 20) with 2.5% gelatin during 2 h. Then membranes were
17
18 incubated overnight at room temperature with the primary antibody diluted in buffer A with 2.5%
19
20 gelatin (1: 300 dilution). The resulting blots were extensively washed with buffer A, and incubated with
21
22 the secondary antiserum coupled to peroxidise (1: 10,000 dilution in buffer A) for 1 h at room
23
24 temperature and washed in buffer A. Finally, an enhanced chemiluminescence kit was used for signal
25
26 detection. Specificity of the immunoreactive proteins was verified by loss of sample immunoreactivity
27
28 when incubated with the antiserum neutralized with the corresponding specific peptide.
29
30
31
32
33
34
35

36 Protein concentrations were measured according to Bradford [24] with BSA as standard.
37
38
39
40

41 **Isolation of RNA**

42
43 Total RNA was isolated from human preadipocytes according to the method of Chomczynski
44
45 and Sacchi [26]. RNA recovery and quality were checked by measuring the 260/280 nm optical density
46
47 ratio and by electrophoresis under denaturing conditions on 2% agarose gel.
48
49
50
51
52

53 **IGF1-R mRNA expression**

54
55 Total RNA (0.5 μg) was extracted and reverse transcribed as previously described [27]. Semi-
56
57
58
59
60

1
2 quantitative PCR method was performed using primer sets indicated in table 1. To ensure that
3
4 amplification of this gene was within the exponential range, different PCR cycles (25-40 cycles) were
5
6 run. Finally, 30 cycles of PCR amplification were chosen to study IGF1-R mRNA expression. The
7
8 second primer set was specific for the 18S cDNA that is used as internal standard. In the same way,
9
10 different PCR cycles (25-40 cycles) were run. Finally 40 cycles of PCR were found to be optimal for
11
12 detection of the 18S mRNA. PCRs were performed with a thermocycler Gene Amp PCR 2400 (Perkin
13
14 Elmer, USA).
15
16
17
18

19 PCR products were analysed on a 2 % agarose gel in 90 mM Tris-borate, 2 mM EDTA buffer
20
21 (TBE) pH 8 and visualized by staining with ethidium bromide and ultraviolet transillumination.
22
23 Quantification was realized with the Bio-1D software (Vilber Lourmat, Marne la Vallée, France).
24
25 Controls without reverse transcriptase were systematically performed in order to detect eventual
26
27 genomic DNA contaminations.
28
29
30
31
32

33 **Cell cycle and apoptosis mRNA expressions**

34
35
36 Total RNA (0.5µg) was reverse transcribed as previously described [27]. Quantitative PCR was
37
38 performed using a LightCycler® instrument from Roche Diagnostics (Basel, Switzerland) with
39
40 QuantiTect SYBR Green PCR Master Mix (Qiagen, Courtaboeuf, France). Primer sets used are
41
42 indicated in table 1. cDNA calibrators were prepared by PCR amplification run to saturation (35 cycles)
43
44 with the appropriate primers. The resulting cDNAs were purified by QIAquick PCR purification Kit
45
46 (Qiagen). The samples showed a unique band in agarose electrophoresis. cDNA copies were calculated
47
48 from the absorbance at 260 nm. Calibrators were defined to contain arbitrary units of human c-fos,
49
50 cyclin D1, p53, bcl2, bax, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs, and all
51
52 calculated concentrations are relative to GAPDH concentrations. In accordance with [28], the choice of
53
54
55
56
57
58
59
60

1
2 GAPDH as housekeeping gene was based on the observation that GAPDH mRNA expression is
3
4 unsensitive to various hormones in human adipose cells. Separate calibration curves for human c-fos,
5
6 cyclin D1, p53, bcl2, bax, and GAPDH were constructed from serial dilutions from 10^8 copies to 100
7
8 copies of cDNA calibrators. Calibration curves were log-linear over the quantification range with
9
10 correlation coefficient (r^2) ≥ 0.99 and efficacy ranging from 1.8 to 2. The intra-assay variability of
11
12 duplicate crossing point (Cp) values never exceeded 0.2 cycle and the inter-assay variability (CV
13
14 value) ranged from 1 to 5 % CV values for the three or four runs of each transcript. Real-time PCR was
15
16 performed as described in [29].
17
18
19
20

21
22 The Second Derivative Maximum Method was used to automatically determine the Cp for the
23
24 individual samples. For each sample, the concentration ratio (target / GAPDH gene, used as internal
25
26 standard) was calculated using the Roche Software. Fold changes in expression were determined by
27
28 calculating the normalized ratio which corresponds to concentration of calibrator situation (without
29
30 effector) / concentration of unknown situation (with effector) (relative quantification).
31
32
33
34
35

36 **Statistical analysis**

37
38 All values were expressed as means \pm SEM from at least five separate experiments. Statistical
39
40 analyses were performed using the non parametric paired Wilcoxon test.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

1- Effects of 17 β -estradiol on human preadipocyte proliferation.

Cell proliferation was first studied by measuring changes in the rate of DNA synthesis ($[^3\text{H}]$ -thymidine incorporation). As shown in Fig. 1a, preadipocyte exposure to the pure ER α antiestrogen (ICI 182,780 at 10 μM) alone caused a significant decrease in preadipose proliferative capacities ($- 36.1 \pm 5.4 \%$). These results suggest that ICI 182,780 may block the effect of estrogens that are produced locally by human preadipocytes.

Experiments were next performed with 17 β -estradiol at 100 nM and as can be seen in the same figure, 17 β -estradiol treatment of cells for 24 h resulted in an increased $[^3\text{H}]$ -thymidine incorporation ($+ 32 \pm 8 \%$). This effect which was confirmed by direct cell counting ($+ 28 \pm 5 \%$) seemed to be dose-independent (data not shown). For comparison, the magnitude of the increase in $[^3\text{H}]$ -thymidine incorporation caused by 10% FCS, used as a positive control, was equivalent to 2.4 ± 0.4 -fold increase compared to control value.

Moreover, when 17 β -estradiol was added simultaneously with ICI 182,780, this antagonist completely abolished the positive effects of estrogens on preadipocyte growth. These results suggest that, in human preadipocytes, the promoting action of estrogens requires ER α .

2- Effects of 17 β -estradiol on some cell cycle gene expression in human confluent preadipose cells.

In order to delineate estrogen-target genes in human preadipocytes, the influence of 17 β -

1
2 estradiol on c-fos, c-myc and, cyclin D1 mRNA expressions was measured by RT-PCR. As shown in
3
4 Fig. 1b, in human preadipose cells, 17 β -estradiol (100 nM) induced both c-myc and cyclin D1 mRNA
5
6 expressions by 2.32 ± 0.25 -fold and 2.36 ± 0.24 -fold, respectively. However, under our experimental
7
8 conditions, 17 β -estradiol did not affect c-fos mRNA expression. These findings indicate that the cell
9
10 cycle genes, c-myc and cyclin D1 seem to be nuclear targets of ER signalling in human preadipocytes.
11
12
13
14
15
16
17

18 **3- Effects of 17 β -estradiol on human preadipose apoptosis.**

19
20
21 To test the influence of estrogens on cell apoptosis, we first used TUNEL assay to determine the
22
23 percentage of labeled apoptotic nuclei. As shown in Fig. 2a, 17 β -estradiol (100 nM) is able to reduce
24
25 significantly DNA fragmentation in human preadipocytes ($- 49 \pm 13\%$) after 48 h exposure when
26
27 apoptosis was induced by TNF α and cycloheximide. Under the same conditions, exposure of cells to 10
28
29 nM IGF1 (a known anti-apoptotic factor) used as control also reduced apoptosis by $43 \pm 21\%$.
30
31 However, no synergic effect on cell apoptosis was observed when both 17 β -estradiol and IGF1 were
32
33 simultaneously added in the culture medium (data not shown).
34
35
36
37
38

39 We next tried to better understand the molecular mechanisms whereby estrogens reduced human
40
41 preadipocyte apoptosis by measuring mRNA expressions of the anti-apoptotic bcl2 gene and of the pro-
42
43 apoptotic Bax and p53 genes. As shown in Fig. 2b, 17 β -estradiol (100 nM) stimulated the expression of
44
45 the anti-apoptotic gene Bcl2 ($\times 1.9 \pm 0.2$) after 24 h exposure. Moreover, expressions of both pro-
46
47 apoptotic genes Bax and p53 were also targets for 17 β -estradiol since a 38 and 49% reduction were
48
49 observed in their expression, respectively. Thus, exposure to estrogens stimulated an *in vitro* anti-
50
51 apoptotic response in human preadipocytes.
52
53
54
55
56
57
58
59
60

4- Effects of 17 β -estradiol on IGF1-R expression in human preadipose cells.

As shown Fig. 3a, by using RT-PCR analysis, we found that IGF1-R mRNA expression was increased by about 5-fold after exposure to 100 nM 17 β -estradiol in human preadipocytes. Moreover, these effects were reversed by simultaneous addition in the culture medium of the ER antagonist ICI 182,780 (10 μ M). Immunoprecipitation experiments also showed a 3-fold induction of IGF1-R protein expression by 17 β -estradiol (100 nM) in human preadipocytes (Fig. 3b-3c). These results suggest that estrogen effects on human preadipocytes could be mediated, at least in part, through modulation of IGF1-R signalling pathway.

Discussion

Adipose tissue is an important site for estrogen biosynthesis and storage [30]. Moreover, the presence of specific receptors for these hormones in both precursor and mature fat cells shows that adipose cells are targets for estrogens [10, 11]. Various observations have led to assign an important role of estrogens in adipocyte development and metabolism (For a review, [31]). For, example, the P450 aromatase- or the ER α -knockout mice displayed a significant and progressive increase in adiposity as compared with their wild type counterpart [32, 33]. More recently, it has been demonstrated that estrogen affect, both *in vivo* and *in vitro*, the expression of key lipogenic and lipolytic genes in human adipocytes [4, 5]. Finally, two studies have shown that in human adipose tissue, estrogens may increase the rate of proliferation *in vitro* [7, 8].

The present study was undertaken to get a better understanding on how estrogens modulate adipocyte proliferation *in vitro*. For this purpose, we first verified that these ovarian steroids effectively promoted preadipose growth under our experimental conditions. Next, we demonstrated that the use of the pure ER α antagonist ICI 182,780 abolished the 17 β -estradiol-induced proliferation. These results are in accordance with previous studies performed in the uterus [34] and support the concept that in human preadipocytes, the promoting action of 17 β -estradiol on growth requires at least in part ER. Otherwise, in agreement with investigations performed in rat adipocytes and in neuroblastoma cells [35], treatment with ICI 182,780 alone negatively affected preadipocyte cell growth. Two hypothesis can be put forward : i) since estrogens are produced locally by human preadipocytes due to *in situ* p450 aromatase expression [30], ICI 182,780 could block the paracrine and/or paracrine action of estrogen on cell growth ; ii) ICI 182,780 is described as a transcriptional inhibitor for certain cell

1
2 cycle genes and this effect is mediated *via* the ER β subtype [36, 37]. Different ER β isoforms have been
3
4 recently characterized in human preadipocytes and their expression generally declined during adipocyte
5
6 differentiation [38].
7

8
9 Cell proliferation is the result of the balance between cell division and apoptosis. In order to
10
11 explain the stimulatory effect of estrogens on human preadipocyte number, we have tested the
12
13 expression of some specific cell cycle and apoptotic genes that could be under the control of estrogens.
14
15 In different tissue and cell types, estrogens are able to induce G1-S phase cell cycle progression through
16
17 increased expression of cyclin D1 and of some proto-oncogenes such as c-fos and c-myc [39, 40]. In
18
19 our study, we have shown that estrogens induce c-myc and cyclin D1 mRNA expressions but not c-fos
20
21 mRNA expression. This suggests that the stimulatory effect of this hormone on human preadipocyte
22
23 growth is due to a direct activation of G1-S phase cell cycle progression. Concerning the apoptotic
24
25 process, as previously reported in other cell types [41, 42], we have also observed that estrogens were
26
27 able to repress DNA fragmentation. This inhibitory effect was accompanied by changes in the
28
29 expression profile of some pro- and anti-apoptotic genes : the pro-apoptotic Bax and p53 mRNA
30
31 expressions were reduced while the anti-apoptotic Bcl2 mRNA expression was increased. Estrogens
32
33 mediated their action by a wide variety of signalling pathways (For a review, [43]). Among these, the
34
35 p42/p44 MAP- and the PI3- kinases played a crucial role in the regulation of both adipose growth and
36
37 apoptosis processes. For example, previous results in our laboratory showed that in rat preadipocytes,
38
39 the mitogenic actions of ovarian hormones were associated to the activation of the p42/p44 MAP
40
41 kinase pathway [44]. Additional experiments are currently in progress in order to delineate the pathway
42
43 by which estrogens transduce their effects on human preadipocytes. Our preliminary experiments failed
44
45 to show any effect of cell-membrane permeable 17 β -estradiol or impermeable estrogen (estradiol
46
47 conjugated to BSA) on p42/p44 MAP kinase activation (data not shown).
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 It is now well established that the regulation of cell growth by estrogens is mediated through
3
4 changes in the expression of some growth factors and/or their receptors. Among these factors, cross-
5
6 talk between IGF1 and ER signalling has been extensively described in various cell types and tissues
7
8 [34, 45, 46]. For example, it has been recently demonstrated that estrogens cause cell proliferation in
9
10 the uterine epithelium of mice and humans through ER α [47]. In this work, they also showed that this
11
12 signalling pathway is mediated by IGF1-R whose activation leads to the stimulation of the PI3 kinase
13
14 pathway leading to cyclin D1 nuclear accumulation and engagement with the canonical cell cycle
15
16 machinery. Moreover, in adipose tissue, IGF1 is considered as an important mitogenic factor. Indeed,
17
18 previous experiments performed in our laboratory with anti-IGF1 antiserum in the culture medium
19
20 revealed that depletion of exogenous and endogenous IGF1 resulted in a significant decrease of cell
21
22 growth in rat and human preadipocyte [12, 29]. In the present paper, we demonstrate that 17 β -estradiol
23
24 increases significantly IGF1-R expression in human preadipocytes. So, in addition to breast cancer cells
25
26 and uterus [34, 45, 46], adipose tissue is another example of tissue where expression of IGF1-R is
27
28 under the control of estrogens. ER-mediated transactivation is a complex process. Estrogens can
29
30 modulate gene transcription by direct binding of the ER to classical estrogen response element [48].
31
32 However, some reports have suggested that transcriptional stimulation triggered by the steroid
33
34 receptors could also involve cooperativity between ER and adjacent promoter elements like AP-1 or
35
36 SP1 sites [49, 50]. This is the case for c-fos gene which expression is dependent on the formation of a
37
38 transcriptionally active ER/SP1 complex binding to an SP1 site [50]. The presence of various SP1
39
40 consensus sequences in the promoter of IGF1-R gene could explain the regulation of this gene by
41
42 estrogens [51].
43
44
45
46
47
48
49
50
51
52

53 Different studies also indicate that IGF1, in an auto-/paracrine manner, can rescue 3T3-L1
54
55 preadipocytes from apoptosis [52, 53] and human preadipocytes as described in this paper and by others
56
57
58

1
2 [23]. Indeed, it has been demonstrated in human adipose tissue that IGF1 induces the expression of the
3
4 anti-apoptotic proteins, bcl-xl and that this protective effect is mediated by PI3 kinase pathway but not
5
6 by the p38 or the p42/p44 MAP kinases [23, 52]. Experiments are currently in progress in our
7
8 laboratory in order to determine the part played by IGF1 signalling in estrogen action in human
9
10 preadipocytes and more precisely the role played by the PI3 kinase pathway.
11
12

13
14 In summary, we have demonstrated that estrogens exert direct regulatory effects on proliferation
15
16 in human preadipocytes. Taken together, our results not only underline the concept of a cross-talk
17
18 between IGF1- and ER- signalling pathways but also indicate that the local estrogen production by
19
20 adipose tissue may act directly or indirectly *via* IGF1-R on the regulation of human adipose tissue
21
22 development.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Bibliography

1. *Bjorntorp P.* Adipose tissue distribution and function. *Int J Obes* 1991; 15 Suppl 2: 67-81.
2. *Bjorntorp P.* The regulation of adipose tissue distribution in humans. *Int J Obes Relat Metab Disord* 1996; 20: 291-302.
3. *D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS.* Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. *J Biol Chem* 2005; 280: 35983-35991.
4. *Lundholm L, Zang H, Hirschberg AL, Gustafsson JA, Arner P, Dahlman-Wright K.* Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. *Fertil Steril* 2008.
5. *Palin SL, McTernan PG, Anderson LA, Sturdee DW, Barnett AH, Kumar S.* 17Beta-estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes. *Metabolism* 2003; 52: 383-388.
6. *Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B.* Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. *J Clin Endocrinol Metab* 2004; 89: 1869-1878.
7. *Roncari DA, Van RL.* Promotion of human adipocyte precursor replication by 17beta-estradiol in culture. *J Clin Invest* 1978; 62: 503-508.
8. *Anderson LA, McTernan PG, Barnett AH, Kumar S.* The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site. *J Clin Endocrinol Metab* 2001; 86: 5045-5051.
9. *Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM.* Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. *Endocr Rev* 2006; 27: 575-605.
10. *Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG.* Identification of estrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue. *Biochem Biophys Res Commun* 1998; 248: 523-526.
11. *Dieudonne MN, Leneuve MC, Giudicelli Y, Pecquery R.* Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. *Am J Physiol Cell Physiol* 2004; 286: C655-661.
12. *Benito M, Valverde AM, Lorenzo M.* IGF-I: a mitogen also involved in differentiation processes in mammalian cells. *Int J Biochem Cell Biol* 1996; 28: 499-510.
13. *Hamelers IH, Steenbergh PH.* Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. *Endocr Relat Cancer* 2003; 10: 331-345.
14. *Huynh H, Nickerson T, Pollak M, Yang X.* Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. *Clin Cancer Res* 1996; 2: 2037-2042.
15. *Molloy CA, May FE, Westley BR.* Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. *J Biol Chem* 2000; 275: 12565-12571.
16. *Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C.* Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. *J Biol Chem* 2000; 275: 18447-18453.
17. *Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F.*

- 1
2 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-
3 7 cells. *Embo J* 1996; 15: 1292-1300.
- 4 18. *Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ.* Linkage of rapid
5 estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.
6 *Mol Endocrinol* 2002; 16: 116-127.
- 7 19. *Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y,*
8 *Nishida E, Kawashima H, Metzger D, Chambon P.* Activation of the estrogen receptor through
9 phosphorylation by mitogen-activated protein kinase. *Science* 1995; 270: 1491-1494.
- 10 20. *Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB.* Role of insulin-like growth factor-I in
11 regulating estrogen receptor-alpha gene expression. *J Cell Biochem* 2000; 76: 605-614.
- 12 21. *Deslex S, Negrel R, Ailhaud G.* Development of a chemically defined serum-free medium for
13 differentiation of rat adipose precursor cells. *Exp Cell Res* 1987; 168: 15-30.
- 14 22. *Niesler CU, Siddle K, Prins JB.* Human preadipocytes display a depot-specific susceptibility to
15 apoptosis. *Diabetes* 1998; 47: 1365-1368.
- 16 23. *Fischer-Posovszky P, Tornqvist H, Debatin KM, Wabitsch M.* Inhibition of death-receptor
17 mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I
18 receptor autocrine circuit. *Endocrinology* 2004; 145: 1849-1859.
- 19 24. *Bradford MM.* A rapid and sensitive method for the quantitation of microgram quantities of
20 protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72: 248-254.
- 21 26. *Chomczynski P, Sacchi N.* Single-step method of RNA isolation by acid guanidinium
22 thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987; 162: 156-159.
- 23 27. *Machinal-Quelin F, Dieudonne MN, Leneuve MC, Pecquery R, Giudicelli Y.* Proadipogenic
24 effect of leptin on rat preadipocytes in vitro: activation of MAPK and STAT3 signaling
25 pathways. *Am J Physiol Cell Physiol* 2002; 282: C853-863.
- 26 28. *Gorzelnik K, Janke J, Engeli S, Sharma AM.* Validation of endogenous controls for gene
27 expression studies in human adipocytes and preadipocytes. *Horm Metab Res* 2001; 33: 625-627.
- 28 29. *Dieudonne MN, Pecquery R, Leneuve MC, Giudicelli Y.* Opposite effects of androgens and
29 estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities
30 and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-
31 activated receptor gamma2. *Endocrinology* 2000; 141: 649-656.
- 32 30. *Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S, Mendelson CR.* Regulation of estrogen
33 biosynthesis by human adipose cells. *Endocr Rev* 1989; 10: 136-148.
- 34 31. *Cooke PS, Naaz A.* Role of estrogens in adipocyte development and function. *Exp Biol Med*
35 (Maywood) 2004; 229: 1127-1135.
- 36 32. *Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ,*
37 *Robertson KM, Yao S, Simpson ER.* Aromatase-deficient (ArKO) mice have a phenotype of
38 increased adiposity. *Proc Natl Acad Sci U S A* 2000; 97: 12735-12740.
- 39 33. *Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS.* Increased adipose tissue in male and
40 female estrogen receptor-alpha knockout mice. *Proc Natl Acad Sci U S A* 2000; 97: 12729-
41 12734.
- 42 34. *Klotz DM, Hewitt SC, Korach KS, Diaugustine RP.* Activation of a uterine insulin-like growth
43 factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen
44 receptor-alpha. *Endocrinology* 2000; 141: 3430-3439.
- 45 35. *Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM.* Rapid membrane effects of
46 steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2 signalling cascade and c-fos immediate early gene transcription. *Endocrinology* 1997; 138:
3 4030-4033.
- 4
5 36. *Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell-*
6 *and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett* 1997; 410: 87-90.
- 7 37. *Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS.*
8 *Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive*
9 *gene sites mediating transactivation or transrepression. Mol Cell Endocrinol* 2003; 206: 13-22.
- 10 38. *Pedersen SB, Bruun JM, Hube F, Kristensen K, Hauner H, Richelsen B. Demonstration of*
11 *estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell*
12 *differentiation and fat depot localization. Mol Cell Endocrinol* 2001; 182: 27-37.
- 13 39. *Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics*
14 *estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol* 1998; 18:
15 4499-4508.
- 16 40. *Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1*
17 *cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential*
18 *regulation of c-Myc and cyclin D1. Mol Cell Endocrinol* 2005; 229: 161-173.
- 19 41. *Conner P. Breast response to menopausal hormone therapy--aspects on proliferation, apoptosis*
20 *and mammographic density. Ann Med* 2007; 39: 28-41.
- 21 42. *Vasconsuelo A, Milanese L, Boland R. 17Beta-estradiol abrogates apoptosis in murine skeletal*
22 *muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway.*
23 *J Endocrinol* 2008; 196: 385-397.
- 24 43. *Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid*
25 *hormones--a focus on rapid, nongenomic effects. Pharmacol Rev* 2000; 52: 513-556.
- 26 44. *Lacasa D, Garcia E, Agli B, Giudicelli Y. Control of rat preadipocyte adipose conversion by*
27 *ovarian status: regional specificity and possible involvement of the mitogen-activated protein*
28 *kinase-dependent and c-fos signaling pathways. Endocrinology* 1997; 138: 2729-2734.
- 29 45. *Zhang S, Li X, Burghardt R, Smith R, 3rd, Safe SH. Role of estrogen receptor (ER) alpha in*
30 *insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells. J Mol*
31 *Endocrinol* 2005; 35: 433-447.
- 32 46. *Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D.*
33 *Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation*
34 *of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol* 1999; 13: 787-
35 796.
- 36 47. *Zhu L, Pollard JW. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through*
37 *insulin-like growth factor 1 signaling. Proc Natl Acad Sci U S A* 2007; 104: 15847-15851.
- 38 48. *Hyder SM, Stancel GM, Loose-Mitchell DS. Presence of an estradiol response region in the*
39 *mouse c-fos oncogene. Steroids* 1991; 56: 498-504.
- 40 49. *Uht RM, Anderson CM, Webb P, Kushner PJ. Transcriptional activities of estrogen and*
41 *glucocorticoid receptors are functionally integrated at the AP-1 response element.*
42 *Endocrinology* 1997; 138: 2900-2908.
- 43 50. *Duan R, Porter W, Safe S. Estrogen-induced c-fos protooncogene expression in MCF-7 human*
44 *breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology* 1998; 139:
45 1981-1990.
- 46 51. *Scheidegger KJ, Cenni B, Picard D, Delafontaine P. Estradiol decreases IGF-1 and IGF-1*
47 *receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective*
48
49
50
51
52
53
54
55
56
57
58
59 20
60

1
2 effects. *J Biol Chem* 2000; 275: 38921-38928.

- 3 52. *Gagnon A, Dods P, Roustan-Delatour N, Chen CS, Sorisky A.* Phosphatidylinositol-3,4,5-
4 trisphosphate is required for insulin-like growth factor 1-mediated survival of 3T3-L1
5 preadipocytes. *Endocrinology* 2001; 142: 205-212.
6
7 53. *Navarro P, Valverde AM, Benito M, Lorenzo M.* Insulin/IGF-I rescues immortalized brown
8 adipocytes from apoptosis down-regulating Bcl-xS expression, in a PI 3-kinase- and map
9 kinase-dependent manner. *Exp Cell Res* 1998; 243: 213-221.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Legends

Figure 1 : Influence of 17 β -estradiol on human preadipocyte proliferation.

(A) Effect of 17 β -estradiol on DNA synthesis.

Growing human preadipocytes were exposed to 0 nM (cont) or 100 nM 17 β -estradiol (E2) concentrations or to the estrogen antagonist ICI 182,780 (100 nM) or to 10% FCS used as positive control in the presence of [³H] thymidine as described under "Materials and Methods". Assays were performed in triplicates for each sample. Results are means \pm SEM of five experiments and are normalized as percentages of the control value (without estradiol) : 1705 \pm 320 cpm / 24h.

* p < 0.03, ** p < 0.01, Wilcoxon test.

(B) Effect of 17 β -estradiol on c-fos, c-myc, cyclin D1 mRNA expressions.

Human confluent preadipocytes were deprived for 18 h and then incubated in the absence (cont) or presence of 17 β -estradiol (100 nM) for the indicated times. Total RNA was extracted and subjected to real time RT-PCR to determine c-fos mRNA level as described under "Materials and Methods". Results are expressed as arbitrary units. Each bar represents the mean \pm SEM of three to four separate experiments.

* p < 0.01, ** p < 0.008 compared with control values, ns = non significant compared with control values, Wilcoxon test.

Figure 2 : Influence of 17 β -estradiol on human preadipocyte apoptosis.

(A) Effects of 17 β -estradiol on DNA fragmentation.

1
2 After 18h in DMEM/F12 supplemented with 2% charcoal-stripped FCS, human preadipocytes were
3
4 cultured during 24h in the presence of TNF α (50 ng/ml) and cycloheximide (10 μ g/ml) in order to
5
6 induce apoptosis. Once apoptosis was triggered, cells were maintained in the same medium during 48 h
7
8 and treated with or without 17 β -estradiol (100 nM) or IGF1 (10 nM). Cells were analysed by TUNEL
9
10 staining and flow cytometer. Results are expressed as arbitrary units. Each bar represents the mean \pm
11
12 SEM of five to seven separate experiments.
13
14
15

16
17 ** p < 0.03 compared with control values, Wilcoxon test.
18
19

20 21 22 **(B) Effects of 17 β -estradiol on p53, bax and bcl2 mRNA expressions.** 23

24 Human confluent preadipocytes were deprived for 18 h in serum-free F12 medium and then incubated
25
26 in the absence (cont) or presence of 17 β -estradiol (100 nM) for the indicated times. Total RNA was
27
28 extracted and subjected to real time RT-PCR to determine c-fos mRNA level as described under
29
30 “Materials and Methods”. Results are expressed as arbitrary units. Each bar represents the mean \pm
31
32 SEM of five to seven separate experiments.
33
34
35

36
37 * p < 0.03 compared with control values, Wilcoxon test.
38
39
40
41

42 **Figure 3: Influence of 17 β -estradiol on IGF1-R expression in human preadipocytes .** 43

44 Human confluent preadipocytes were deprived for 18 h in serum-free F12 medium and then incubated
45
46 in the absence (cont) or presence of 17 β -estradiol (100 nM) for 24 h.
47
48
49
50
51
52

53 **A: Effects of 17 β -estradiol on IGF1-R mRNA expression.** 54

55 Results are expressed as arbitrary units. Each bar represents the mean \pm SEM of five to seven separate
56
57
58
59
60

1
2 experiments.

3
4 **p < 0.03 compared with control values, ns = non significant compared with control values,
5
6
7 Wilcoxon test.

8
9
10
11 **B: Representative Western Blot of the effects of 17 β -estradiol on IGF1-R expression.**

12
13 Cell lysates were subjected to SDS-PAGE, immunoblotted and quantified as described under
14
15 “Materials and Methods”.
16

17
18
19
20
21 **C: Densitometric analysis of the effects of 17 β -estradiol on IGF1-R protein expression.**

22
23 Results are expressed as arbitrary units. Each bar represents the mean \pm SEM of four to five separate
24
25
26 experiments.

27
28
29 * p < 0.05 compared with control values, Wilcoxon test.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 3A




Figure 3B





Figure 3C



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1 : Primer pairs used for RT-PCR

Primer sets	Sequence	PCR product (bp)
Cyclin D1 Sense Antisense	5' GAG TGG CCG CAG CCG C 3' 5' CAG TTC GCG GCT CAG CTG TT 3'	69
c-fos Sense Antisense	5' GCT ATG CTC TTC ACC TAT 3' 5' GTC ATT GTC ATT ATC AGC 3'	111
c-myc Sense Antisense	5' GAC GCG GGG AGG CTA TTC TG 3' 5' GAC TCG TAG AAA TAC GGC TGC ACC GAGTC 3'	236
IGF1-R Sense Antisense	5' AAT AAC ATT GCT TCA GAG CTG 3' 5' GAT GGT GCC GTC GGC ATA CTT 3'	933
18 S Sense Antisense	5' ATT CCA GCT CCA ATA GCG 3' 5' CAC TCA GCT AAG AGC ATG G 3'	172
GAPDH Sense Antisense	5' ACC CAC TCC TCC ACC TTT G 3' 5' CTC TTG TGC TCT TGC TGG G 3'	178
p53 Sense Antisense	5' ACT AAG CGA GCA CTG CCC AA 3' 5' ATG GCG GGA GGT AGA CTG AC 3'	231
bcl2 Sense Antisense	5' ATG TGT GTG GAC AGC GTC AAC C 3' 5' TGA GCA GAG TCT TCA GAG ACA GCC 3'	196
Bax Sense Antisense	5' CAA ACT GGT GCT CAA GGC C 3' 5' GCA CTC CCG CCA CAA AGA T 3'	188